EM-4350
EM-4350 is a novel pharmaceutical compound currently under investigation for its potential therapeutic applications in the treatment of chronic pain and neuropathic disorders. This compound is part of a new class of drugs known as selective ion channel modulators, which target specific ion channels in the nervous system to modulate pain signaling pathways.
Mechanism of Action[edit | edit source]
EM-4350 functions by selectively inhibiting the activity of certain voltage-gated sodium channels, particularly those expressed in peripheral sensory neurons. These channels are crucial for the initiation and propagation of action potentials in neurons, and their dysregulation is often associated with chronic pain conditions. By modulating these channels, EM-4350 reduces neuronal excitability and diminishes pain perception.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of EM-4350 is characterized by its high oral bioavailability and moderate protein binding. It undergoes hepatic metabolism primarily via the cytochrome P450 enzyme system, with a half-life of approximately 12 hours, allowing for twice-daily dosing. The drug is primarily excreted through the renal pathway.
Clinical Trials[edit | edit source]
EM-4350 is currently in Phase II clinical trials, where it is being evaluated for efficacy and safety in patients with diabetic neuropathy and postherpetic neuralgia. Preliminary results have shown promising reductions in pain scores with a favorable side effect profile.
Adverse Effects[edit | edit source]
Common adverse effects reported in clinical trials include mild dizziness, nausea, and fatigue. These effects are generally transient and resolve with continued use. No serious adverse events have been directly attributed to EM-4350 thus far.
Potential Applications[edit | edit source]
Beyond its use in chronic pain management, EM-4350 is being explored for its potential in treating epilepsy and other neurological disorders characterized by hyperexcitability of neurons.
Also see[edit | edit source]
- Chronic pain management
- Neuropathic pain
- Voltage-gated sodium channel
- Pharmacokinetics
- Clinical trial phases
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
